Objective: To evaluate and compare interobserver variation in interpretation of intrapartum cardiotocograms.
Subjects: Fifteen senior (experience >4 years) and 16 junior (experience < or =4 years) obstetricians from 10 delivery units.
Design: Thirty-one obstetricians interpreted intrapartum cardiotocographic (CTG) readings from 22 parturients.
Acta Obstet Gynecol Scand
April 2006
Background: This study describes reproductive health, use of contraception, age at menopause, the prevalence of climacteric complaints, and hormone replacement therapy among Estonian women born in 1937-47.
Methods: A sample of 800 Estonian women born in 1937-47 was composed at random from the Estonian population registry in 1997. A postal questionnaire was sent to all participants.
Objective: To compare the combination of intravenous propranolol and oxytocin with oxytocin only in augmentation of labour.
Study Design: A prospective randomized double-blind study in an obstetric department of a large university hospital in Finland. A total of 107 parturients with arrested first stage of labour owing to inadequate uterine contractility were randomized to receive intravenously once or twice a 2 mg dose of propranolol or placebo combined with oxytocin infusion.
Acta Obstet Gynecol Scand
June 2005
Background And Aim: To compare perinatal outcome in groups of planned vaginal breech delivery, elective cesarean section with the fetus in breech presentation, and planned vaginal delivery with the fetus in cephalic presentation in a university hospital with a tradition of managing breech deliveries by the vaginal route.
Methods: A cohort study from a 7-year period 1995-2002, including 590 planned vaginal deliveries with a term (> 37 weeks) singleton fetus in breech presentation, 396 elective cesarean sections with a term singleton fetus in breech presentation, and 590 control women intending vaginal delivery with a singleton term fetus in cephalic presentation.
Results: The Apgar scores were lower in the group of planned vaginal breech delivery, but in other outcome measures there were no significant intergroup differences.
Objective: To compare ospemifene and raloxifene regarding their effects on hormones, lipids, genital tract, and tolerability in postmenopausal women.
Design: A randomized, double-blind study in which 118 healthy postmenopausal women received 30 (n = 29), 60 (n = 30), or 90 mg (n = 30) of ospemifene or 60 mg (n = 29) of raloxifene for 3 months.
Results: There were no significant differences in the baseline characteristics between study groups.